Webcast Teaches Physicians About Advances in Liver Disease. Last summer, experts from around the world worked together to rename Nonalcoholic fatty liver disease into Metabolic dysfunction-associated steatotic liver disease or MASLD. And earlier this year at the end of March 2024, the FDA approved the first drug to treat MASLD. Meanwhile another promising agent is already in the pipeline, currently undergoing phase 3 clinical trials.
To share more about the advances in some of the most common liver conditions including MASLD, autoimmune hepatitis, and Hepatocellular carcinoma, We’ve invited one of Ohio State University’s Transplant Hepatology experts. We are pleased to introduce Assistant Professor of Gastroenterology and Hepatology Dr Vivek Mendiratta.
What you’ll learn in this webcast
As a result of this educational activity, webcast participants will be able to:
- Understand steatotic liver disease including diagnosis, management, and pharmacologic treatment options.
- Learn about the newest advances in hepatocellular carcinoma including the role of combination therapy, novel biomarkers, and liver transplantation.
You’ll also learn about the following:
- Treatment & Monitoring
- Weight Loss
- Liver Transplantation
You can find this and many other MedNet21 programs on the OSU – CCME website.
Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.